Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces that five presentations in relation to the potential of Imeglimin, marketed under the brand name TWYMEEG ® in Japan, will be made at the 85 th Scientific Sessions of the American Diabetes Associations, from June 20 to 23, 2025, in Chicago, Illinois (U.S.A).
A total of 5 publications, including results from 2 clinical trials and 3 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. Main topics include:
Potential of Imeglimin to Improve Inflammation and Fibrosis in Diabetic Kidney Disease, by Yoshimi Muta, from Fukuoka University (Fukuoka, Japan)
The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model, by Ryota Usui, from Kansai Electric Power Hospital (Osaka, Japan)
Attempts to Identify Predictors of Glycemic Control with Imeglimin—Machine Learning Analysis Using Clinical Trial Data, by Katsuhiko Hagi, from Sumitomo Pharma
Therapeutic Potential of Imeglimin for Diabetic Neuropathy—Neuroprotective Effects in Type 1 Diabetic Rats, by Wataru Nihei, from the Aichi Gakuin University School of Pharmacy's Laboratory of Medicine (Nagoya, Japan)
Effect of Imeglimin on Periodontitis in Streptozotocin-Induced Diabetic Rats, by Shun Kondo, from the Aichi Gakuin University's School of Dentistry (Nagoya, Japan)
Thomas Kuhn, CEO of Poxel, stated: 'We are very pleased to see that the potential of Imeglimin (TWYMEEG ®) in the fight against type 2 diabetes and its associated conditions continues to generate enthusiasm within the scientific community, with the support of our partner Sumitomo Pharma. The presentations on TWYMEEG ®, at the world's most important academic event on diabetes provide further confirmation of its value as a treatment for diabetic patients.'
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio at SNMMI Annual Meeting
ATLANTA--(BUSINESS WIRE)-- Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec 2 Software suite and advances from Mirion Technologies. Debuting at the 2025 SNMMI Annual Meeting Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a groundbreaking, solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose ® VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company: The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio ec 2 Software Suite: ec 2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™ QMS, NMIS™, and BioRx™ will be available throughout the SNMMI Annual Meeting. Apex-Guard™ Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo ® Probe and RDS-Med™ Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™ Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™ Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. 'As the nuclear medicine and molecular imaging landscape evolves, Mirion is committed to leveraging our deep expertise in ionizing radiation to serve our customers and ensure safe, efficient operations at every step,' said Luis Rivera, Executive Vice President of Mirion Medical. 'From research to production to patient care, Mirion Medical and Mirion Technologies alike are developing solutions to drive higher quality. We look forward to demonstrating how these solutions can shape a more connected future.' Commitment to Patient Care and Safety Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging. About Mirion Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. The Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. ©2025 Mirion. All rights reserved. Instadose®VUE, BioTrax™ QMS, NMIS™, BioRx™, CSPevo™, Apex-Guard™, IC3™, and iCAM™ are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.
New York Post
2 hours ago
- New York Post
Children's cough syrup recalled due to possibly deadly food poisoning risk: ‘Stop using it immediately'
Parents: You might want to check your medicine cabinet. A New York-based pharmaceutical company is voluntarily recalling several batches of a popular children's cough syrup over fears they may be contaminated with harmful bacteria. The Food and Drug Administration is urging consumers to 'stop using it immediately' if they have any of the affected lots of Little Remedies® Honey Cough Syrup, according to an alert issued by the agency on Wednesday. Advertisement 3 The recalled product may contain Bacillus cereus Little Remedies The affected bottles were sold both in stores and online between Dec. 14, 2022, and June 4, 2025. The syrup comes in a 4-fluid-ounce amber bottle, packaged in an outer carton. Lot codes, which identify the recalled products, can be found on the bottle label and the bottom of the box. Advertisement The following five batches are affected: 3 FDA No other Little Remedies products are part of the recall. Syrup affected by the recall may be tainted with Bacillus cereus, a bacteria that can lead to two types of food-borne illnesses, according to the FDA. Advertisement One causes nausea, vomiting, and stomach cramps within six hours of exposure. The other triggers diarrhea and cramping, typically 8 to 16 hours after use. 3 The product is intended for children ages 1 year and older. redpepper82 – 'While healthy individuals may suffer only short-term illness, exposure to high levels of B. cereus can be fatal,' the agency said in an alert. So far, no illnesses have been reported. The FDA recommends that anyone experiencing symptoms seek medical attention and report any adverse reactions through their website. Advertisement Manufacturer, Medtech, is offering full refunds for the recalled products. Customers can contact the company directly by email at medicalaffairs@ through its website or by phone at (800) 754-8853 from 8:30 a.m. – 5:30 p.m. Monday through Friday.
Business Wire
5 hours ago
- Business Wire
The Sun's Out. So Is the Secret to UV and Sun Support from Within.
KAILUA-KONA, Hawaii--(BUSINESS WIRE)--A new conversation in sun care is emerging — one that goes beyond the surface and into the science of supporting skin from within with microalgae. Nutrex Hawaii, a wholly owned subsidiary of Cyanotech Corporation and producer of BioAstin Hawaiian Astaxanthin, is leading that evolution with more than 40 years of natural microalgae cultivation, research, and innovation on Hawaii's Kona Coast. For years, health guidance has focused on external protection - sunscreen, hats, UV clothing, and sunglasses. That's smart. But science has evolved — and so has understanding of support from within. Share 'For years, public health guidance has focused on external protection — sunscreen, shade, hats, protective clothing, and sunglasses. That's smart and we agree. Everyone on our Hawaiian farm follows these practices,' said Collette Kakuk, Chief Strategic Officer at Nutrex Hawaii. 'But science has evolved — and so has our understanding of skin support from within.' The Science Behind the Shield. BioAstin Hawaiian Astaxanthin is one of nature's most powerful antioxidants and works in two ways to help protect skin under the sun: Neutralizes UV-induced free radicals, supporting healthy inflammation response, collagen integrity, and skin elasticity Accumulates in the skin's layers, embedding in cell membranes to deliver continuous, inside-out defense before damage begins With only 6–12mg daily (one small softgel), BioAstin® Hawaiian Astaxanthin® builds resilience and provides antioxidant support from within ☨ after about 3 to 4 weeks. Not a Sunscreen Replacement — A Sun Care Reinforcement Skin cancer is on the rise globally, with the United States consistently ranking among the highest reported cases. According to National Cancer Institute estimates, there were 100,640 new cases of skin melanomas and 8,290 related deaths in the United States in 2024. The American Academy of Dermatology Association estimates that one in five Americans will develop skin cancer in their lifetime. Finally, according to the Skin Cancer Foundation, about 90 percent of nonmelanoma skin cancers are associated with exposure to ultraviolet (UV) radiation from the sun. The following have long been advocated for with regard to sun safety: Using broad-spectrum, reef-safe sunscreen Wearing a wide brimmed hat & protective clothing Wearing UV-blocking sunglasses Seeking shade during peak hours BioAstin® doesn't aim to replace these measures — but to reinforce them. 'Internal support fills a critical gap in modern sun care,' said Kakuk. 'It's not a replacement for sunscreen, but a crucial internal layer of adjunctive UV and sun support for responsible sun care — especially given how sunscreen is used in the real world: it sweats off, washes off, gets missed in spots, or isn't reapplied as often as it should be.' More Than Skin Deep: Full-Body Support for Life Under the Sun As an antioxidant 6,000x stronger than Vitamin C — BioAstin® helps provide internal support against UV and sun exposure ☨ — it's also one of the rare natural antioxidants capable of crossing both the blood-brain and blood-retinal barriers, entering deep into the mitochondria, our cellular engines where energy is produced and oxidative damage is most critical. This extraordinary bioactivity supports a wide range of clinically documented benefits for full-body wellness, including eye, skin, joint, heart, and brain health ☨, as well as post-exercise recovery ☨ and cellular support ☨. 'Here in Hawaii, we've long known BioAstin® provides powerful internal antioxidant support. From beach goers, lifeguards, surfers, and tourists to outdoor workers and healthy agers, we're proud to expand the sun care conversation with superior microalgae that supports the body in much the same way it functions in nature,' said Kakuk. Nature's Blueprint for Sun Defense: Biomimicry in Action In the natural world, the freshwater microalga Haematococcus pluvialis faces harsh environmental stress, including intense UV radiation from the sun. To survive, it produces high levels of astaxanthin, a powerful red carotenoid antioxidant, to form a protective barrier against UV damage and oxidation. This same mechanism is what makes astaxanthin so extraordinary for humans. The way astaxanthin protects microalgae from UV-induced stress in nature is the same way it works within the human body — helping to support skin from within. It's a striking example of biomimicry, where nature's survival strategies are mirrored in how it functions in the body. 'In nature, this unique microalgae survives intense UV stress by producing astaxanthin — a powerful antioxidant and striking example of biomimicry,' said Dr. Gerry Cysewski, PhD, Founder and Chief Scientific Officer of Nutrex Hawaii. 'I've spent my career studying and cultivating these remarkable organisms because of their unique biochemical properties and continually unfolding potential. Supporting our bodies under the sun with the same molecule nature uses to protect its own life forms isn't just smart science — it's common sense.' BioAstin harnesses this biological brilliance with natural astaxanthin farm grown outdoors — never synthetic or bio-identical versions produced in labs under LED lights. BioAstin is cultivated in sustainable, open-air ponds on Hawaii's Kona Coast, where intense natural sunlight triggers the microalga's defense response to produce astaxanthin. A Legacy Rooted in Science, Sustainability, and Hawaii Nutrex Hawaii is one of Hawaii's longest-standing farm-based supplement brands, having sustainably cultivated microalgae on the Kona Coast for over 40 years. Every harvest is traceable, rigorously tested, and grown with care using sustainable aquaculture practices in one of the world's sunniest climates. See Where It's Grown – Video Link About Nutrex Hawaii: For over 40 years, Nutrex Hawaii has sustainably cultivated microalgae to support health and wellness. Grown on a purpose-built 96-acre farm on the pristine Kona Coast of Hawaii, its flagship products— BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® —are trusted worldwide. Nutrex Hawaii products are distributed across the United States and internationally through natural and specialty retailers, healthcare professionals, and e-commerce platforms including and ☨ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
